BARICITINIB IN THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN CHINA: 24-WEEK RESULTS OF POSTMARKETING SAFETY STUDY

被引：0
|
作者：
Wu, C. Y. [1 ]
Wang, Q. [1 ]
Shi, J. [2 ]
Zhang, X. [3 ]
Du, R. [4 ]
Gu, J. [5 ]
Liu, Q. H. [6 ]
Yu, J. [1 ,7 ]
Xu, J. W. [1 ,7 ]
Zhang, Y. J. [1 ,7 ]
Zhu, H. [1 ]
Li, M.
Zeng, X.
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp PUMCH, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China
[2] Yiyang Cent Hosp, Dept Rheumatol & Clin Immunol, Yiyang, Peoples R China
[3] Zibo Cent Hosp, Dept Rheumatol & Clin Immunol, Zibo, Peoples R China
[4] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Tongji Med Coll, Dept Rheumatol & Clin Immunol, Wuhan, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol & Clin Immunol, Guangzhou, Peoples R China
[6] Hubei Univ Med, Sinopharm Dongfeng Gen Hosp, Dept Rheumatol & Clin Immunol, Shiyan, Peoples R China
[7] Eli Lilly & Co, LCDDMAC, Shanghai, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Real-world evidence; Safety; Rheumatoid arthritis;
D O I：
10.1136/annrheumdis-2023-eular.2148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0455 AB0
引用
下载
收藏
页码：1418 / 1418
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of baricitinib in patients with rheumatoid arthritis and inappropriate response to conventional disease-modifying anti-rheumatic drugs: 24-week phase 3 RA-BUILD study summary results
    Emery, P.
    Krogulec, M.
    Blanco Alonso, R.
    Rossini, M.
    Raeman, F.
    Walker, D.
    Ghizdavescu, Petru A.
    Irto, I.
    Luz Rentero, M.
    Casillas, M.
    de la Torre, I
    Dougados, M.
    SWISS MEDICAL WEEKLY, 2016, 146 : 3S - 3S
  • [32] Adalimumab in psoriatic arthritis: 24-week results of a phase III study
    Mease, P
    Gladman, D
    Ritchlin, C
    Weinberg, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P2 - P2
  • [33] SAFETY PROFILE OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS
    Genovese, M.
    Smolen, J.
    Takeuchi, T.
    Hyslop, D.
    MacIas, W.
    Rooney, T.
    Chen, L.
    Dickson, C.
    Riddle, J.
    Cardillo, T.
    Winthrop, K.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 28 - 28
  • [34] BUDGET IMPACT ANALYSIS OF TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH BARICITINIB IN THE RUSSIAN FEDERATION
    Yagudina, R.
    Kulikov, A.
    Serpik, V
    Protsenko, M.
    VALUE IN HEALTH, 2019, 22 : S903 - S903
  • [35] Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE
    Li, Zhan-Guo
    Hu, Jian-Kang
    Li, Xiang-Pei
    Yang, Yue
    Li, Xing-Fu
    Xu, Jian-Hua
    Zhang, Xiao
    Xu, Jian
    Bao, Chun-De
    He, Dong-Yi
    Li, Zhi-Jun
    Wang, Guo-Chun
    Zuo, Xiao-Xia
    Liu, Yi
    Xiao, Zheng-Yu
    Chen, Jin-Wei
    Xin, Xia-Fei
    Li, Jing-Yang
    Jiang, Lin-Di
    Liu, Meng-Ru
    Ji, Fei
    Li, Chen-Ge
    ADVANCES IN THERAPY, 2021, 38 (01) : 772 - 781
  • [36] Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE
    Zhan-Guo Li
    Jian-Kang Hu
    Xiang-Pei Li
    Yue Yang
    Xing-Fu Li
    Jian-Hua Xu
    Xiao Zhang
    Jian Xu
    Chun-De Bao
    Dong-Yi He
    Zhi-Jun Li
    Guo-Chun Wang
    Xiao-Xia Zuo
    Yi Liu
    Zheng-Yu Xiao
    Jin-Wei Chen
    Xia-Fei Xin
    Jing-Yang Li
    Lin-Di Jiang
    Meng-Ru Liu
    Fei Ji
    Chen-Ge Li
    Advances in Therapy, 2021, 38 : 772 - 781
  • [37] Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    RHEUMATOLOGY AND THERAPY, 2021, 8 (02) : 863 - 876
  • [38] Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
    SiNi Li
    JianHe Li
    LiuBao Peng
    YaMin Li
    XiaoMin Wan
    Rheumatology and Therapy, 2021, 8 : 863 - 876
  • [39] Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study
    Tanaka, Yoshiya
    Ishii, Taeko
    Cai, Zhihong
    Schlichting, Douglas
    Rooney, Terence
    Macias, William
    MODERN RHEUMATOLOGY, 2018, 28 (01) : 20 - 29
  • [40] Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study
    Cohen, Stanley
    Fiechtner, Justus
    Mease, Philip
    Kaine, Jeffrey
    Kavanaugh, Arthur
    Cheng, Yi-Lin
    Chou, Claire
    Cheng, Ting-Ying
    Lin, Shih-Yao
    Genovese, Mark
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345